Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study

M. Trněný, A. Avigdor, MS. McKinney, S. Paneesha, BE. Wahlin, JS. Hrom, D. Cunningham, N. Morley, M. Canales, M. Bastos-Oreiro, D. Belada, L. Devizzi, F. Zheng, DJ. DeMarini, W. Jiang, P. Jiang, RC. Lynch

. 2023 ; 63 (-) : 102130. [pub] 20230818

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23015343

BACKGROUND: Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. This phase 2 study (CITADEL-203; NCT03126019, EudraCT 2017-001624-22) assessed efficacy and safety of parsaclisib monotherapy in patients with R/R follicular lymphoma (FL). METHODS: Patients ≥18 years of age with histologically confirmed R/R FL (grade 1-3a) and prior treatment with ≥2 systemic therapies received parsaclisib 20 mg once daily (QD) for 8 weeks then parsaclisib 20 mg once weekly (weekly dosing group [WG]) or parsaclisib 20 mg QD for 8 weeks then parsaclisib 2.5 mg QD (daily dosing group [DG]); DG was selected for further assessment. Primary endpoint was objective response rate (ORR). FINDINGS: At data cut-off (January 15, 2021), 126 patients had been treated (WG: n = 23; DG: n = 103). ORR (95% confidence interval [CI]) was 77.7% (68.4-85.3) with a complete response rate (95% CI) of 19.4% (12.3-28.4) in DG; median (95% CI) duration of response was 14.7 months (10.4-not estimable [NE]), median progression-free survival was 15.8 months (11.0-NE), and median overall survival was not reached. The most common any-grade treatment-emergent adverse events (TEAEs) among all treated patients included diarrhoea (n = 48, 38.1%), nausea (n = 31, 24.6%), and cough (n = 28, 22.2%); the most common grade ≥3 TEAEs were diarrhoea (n = 15, 11.9%), neutropenia (n = 13, 10.3%), and colitis (n = 7, 5.6%). Dose interruption, reduction, and discontinuation from TEAEs occurred in 46.8% (n = 59), 17.5% (n = 22), and 23.8% (n = 30) of patients, respectively. INTERPRETATION: Treatment with parsaclisib demonstrated rapid and durable responses, and a manageable safety profile in patients with R/R FL. FUNDING: Incyte Corporation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015343
003      
CZ-PrNML
005      
20231020093616.0
007      
ta
008      
231010s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.eclinm.2023.102130 $2 doi
035    __
$a (PubMed)37662520
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Trněný, Marek $u First Department of Medicine - Hematology, Charles University General Hospital, Prague, Czech Republic
245    10
$a Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study / $c M. Trněný, A. Avigdor, MS. McKinney, S. Paneesha, BE. Wahlin, JS. Hrom, D. Cunningham, N. Morley, M. Canales, M. Bastos-Oreiro, D. Belada, L. Devizzi, F. Zheng, DJ. DeMarini, W. Jiang, P. Jiang, RC. Lynch
520    9_
$a BACKGROUND: Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. This phase 2 study (CITADEL-203; NCT03126019, EudraCT 2017-001624-22) assessed efficacy and safety of parsaclisib monotherapy in patients with R/R follicular lymphoma (FL). METHODS: Patients ≥18 years of age with histologically confirmed R/R FL (grade 1-3a) and prior treatment with ≥2 systemic therapies received parsaclisib 20 mg once daily (QD) for 8 weeks then parsaclisib 20 mg once weekly (weekly dosing group [WG]) or parsaclisib 20 mg QD for 8 weeks then parsaclisib 2.5 mg QD (daily dosing group [DG]); DG was selected for further assessment. Primary endpoint was objective response rate (ORR). FINDINGS: At data cut-off (January 15, 2021), 126 patients had been treated (WG: n = 23; DG: n = 103). ORR (95% confidence interval [CI]) was 77.7% (68.4-85.3) with a complete response rate (95% CI) of 19.4% (12.3-28.4) in DG; median (95% CI) duration of response was 14.7 months (10.4-not estimable [NE]), median progression-free survival was 15.8 months (11.0-NE), and median overall survival was not reached. The most common any-grade treatment-emergent adverse events (TEAEs) among all treated patients included diarrhoea (n = 48, 38.1%), nausea (n = 31, 24.6%), and cough (n = 28, 22.2%); the most common grade ≥3 TEAEs were diarrhoea (n = 15, 11.9%), neutropenia (n = 13, 10.3%), and colitis (n = 7, 5.6%). Dose interruption, reduction, and discontinuation from TEAEs occurred in 46.8% (n = 59), 17.5% (n = 22), and 23.8% (n = 30) of patients, respectively. INTERPRETATION: Treatment with parsaclisib demonstrated rapid and durable responses, and a manageable safety profile in patients with R/R FL. FUNDING: Incyte Corporation.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Avigdor, Abraham $u Institute of Hematology, Sheba Medical Center, Ramat Gan, Israel $u Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
700    1_
$a McKinney, Matthew S $u Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke Cancer Institute, Durham, NC, USA
700    1_
$a Paneesha, Shankara $u Department of Haematology & Stem Cell Transplantation, Birmingham Heartlands Hospital, Birmingham, UK
700    1_
$a Wahlin, Björn E $u Karolinska Institutet, Department of Medicine, Huddinge, and Karolinska University Hospital, Unit for Hematology, Stockholm, Sweden
700    1_
$a Hrom, John S $u Forrest General Hospital and Hattiesburg Clinic of Hematology and Oncology, Hattiesburg, MS, USA
700    1_
$a Cunningham, David $u Royal Marsden Hospital, NHS Foundation Trust, London and Surrey, UK
700    1_
$a Morley, Nicholas $u Sheffield Teaching Hospital, NHS Foundation Trust, Sheffield and London, UK
700    1_
$a Canales, Miguel $u Hospital Universitario La Paz, Madrid, Spain
700    1_
$a Bastos-Oreiro, Mariana $u Hematology Department, Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain
700    1_
$a Belada, David $u Fourth Department of Internal Medicine - Hematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech Republic
700    1_
$a Devizzi, Liliana $u Division of Hemathology and Stem Cell Transplantation, IRCCS Istituto Nazionale Tumori, Milan, Italy
700    1_
$a Zheng, Fred $u Incyte Corporation, Wilmington, DE, USA
700    1_
$a DeMarini, Douglas J $u Incyte Corporation, Wilmington, DE, USA
700    1_
$a Jiang, Wei $u Incyte Corporation, Wilmington, DE, USA
700    1_
$a Jiang, Ping $u Incyte Corporation, Wilmington, DE, USA
700    1_
$a Lynch, Ryan C $u University of Washington School of Medicine, Fred Hutch Cancer Center, Seattle, WA, USA
773    0_
$w MED00200566 $t EClinicalMedicine $x 2589-5370 $g Roč. 63, č. - (2023), s. 102130
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37662520 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20231020093609 $b ABA008
999    __
$a ok $b bmc $g 1997101 $s 1201705
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 63 $c - $d 102130 $e 20230818 $i 2589-5370 $m EClinicalMedicine $n EClinicalMedicine $x MED00200566
LZP    __
$a Pubmed-20231010

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace